MTOR and head and neck squamous cell carcinoma: Indeed, we and others have demonstrated this pathway dependence in a large series of genetically-defined and chemically-induced preclinical HNSCC experimental models by inhibiting mTOR with rapamycin and its analogs, which inhibit the activity of mTORC1 via binding to FKBP-12 and forming a ternary com­plex with mTOR [14-18].